Reglan & Tardive Dyskinesia

Schmidt & Clark, LLP is No Longer Taking These Cases - If you feel that you may have a potential case, we urge you to contact another law firm adequately suited to handle your case.

Studies since the mid-1980’s have shown a correlation between Tardive Dyskinesia and the use of Reglan

Reglan & Tardive Dyskinesia: an Overview

Tardive Dyskinesia (TD) includes voluntary spasms and movements such as grimacing, tongue protrusion, rapid eye blinking, and rapid movements of extremities. TD patients often suffer from depression, and there is no known cure for the ailment.

In February 2009, the FDA required Reglan to be sold with a “black box” warning and that the drug label be revised. However, Reglan was sold for years with inadequate safety warnings and prescribed for use for more than 12 weeks.

In lawsuits filed against Reglan manufacturers, patients who developed TD allege that the drug companies failed to adequately warn physicians and their patients of the association between Reglan and TD, as well as the heightened danger of developing TD from use of Reglan for more than 12 weeks.

Awards & recognition